Navigation Links
SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
Date:6/10/2013

MOUNTAIN VIEW, Calif., June 10, 2013 /PRNewswire/ -- SanBio Inc., a California-based regenerative medicine company, announced today that the U.S. Food and Drug Administration has approved their Investigational New Drug application (IND) for the use of SB623, a novel allogeneic stem cell therapy product, in patients suffering from traumatic brain injuries (TBI's). This approval allows the company to proceed with a Phase 1/2a clinical trial testing the safety and feasibility of the therapy. The clinical trial is expected to be carried out at several major hospitals in the United States.

"This is the second clinical program for SanBio," said Keita Mori, SanBio's Chief Executive Officer, "we see this as a clear validation of our development program and a significant broadening of the therapeutic application of our lead product SB623 for the treatment of unaddressed chronic neurological deficits."

"We measure the responses of TBI patients to physical therapy every day. Progress is often painfully slow and incremental," said Dr. Daniel Lu, Principal Investigator, Neuroplasticity and Repair Laboratory and Director, Neuromotor Recovery Research Center, University of California, Los Angeles, "If this new cell therapy approach improves outcomes it could have a dramatic positive effect on many lives."

About Traumatic Brain Injury: According to the Center for Disease Control and Prevention, more the 1.7 million people in the United States sustain a traumatic brain injury each year, resulting in approximately 50,000 deaths and 275,000 hospitalizations. Many of these more severely injured patients suffer permanent disabilities, including loss of motor function and cognitive impairment. Other than physical rehabilitation there is no effective therapy. Direct medical costs and indirect costs such as lost productivity of TBI totaled an estimated $76.5 billion in the United States in 2000.

About SB623: SB623 is a proprietary cell therapy product consisting of cells derived from genetically modified bone marrow stromal cells obtained from healthy adult donors.  SB623 is administered adjacent to the damaged area of the brain. SB623 functions by producing factors that aid the regenerative process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

For more information: www.san-bio.com


'/>"/>
SOURCE SanBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , Jan 20, 2017 Research and ... Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), ... to their offering. ... Global Hearing Aids Market Sales Volume, Company Analysis ... fast-evolving, high-growth hearing aid industry. The growing prevalence ...
(Date:1/20/2017)... 20, 2017 Stock-Callers.com today evaluates the ... SGYP ), Novo Nordisk A/S (NYSE: NVO ), ... Therapeutics Holdings Inc. (NASDAQ: PTX ). These stocks ... 19 th , 2017, finishing near its session lows. As ... over 0.7%, while shares of health care companies in the ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global business ... recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly ... to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming ... friends, and community. “Coming Home 2017” will be held on Friday January ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics ... Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three comfortable ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
(Date:1/21/2017)... Texas (PRWEB) , ... January 21, 2017 , ... ... performed by Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its creos™ ... features two surgeries performed by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and Roadie, ... use or need, from clothes to couches to dressers and bicycles. Roadie — the ... to the nearest Goodwill donation center through February 28th. , “January is an ...
Breaking Medicine News(10 mins):